title: Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial.
abstract: OBJECTIVE
  To test whether oral or vaginal lactobacillus can prevent vulvovaginitis after antibiotic treatment.
  
  
  METHODS
  Randomised, placebo controlled, double blind, factorial 2x2 trial.
  
  
  METHODS
  Fifty general practices and 16 pharmacies in Melbourne, Australia.
  
  
  METHODS
  Non-pregnant women aged 18-50 years who required a short course of oral antibiotics for a non-gynaecological infection: 278 were enrolled in the study, and results were available for 235.
  
  
  METHODS
  Lactobacillus preparations taken orally or vaginally, or both, from enrollment until four days after completion of their antibiotic course.
  
  
  METHODS
  Participants' reports of symptoms of post-antibiotic vulvovaginitis, with microbiological evidence of candidiasis provided by a self obtained vaginal swab.
  
  
  RESULTS
  Overall, 55/235 (23% (95% confidence interval 18% to 29%)) women developed post-antibiotic vulvovaginitis. Compared with placebo, the odds ratio for developing post-antibiotic vulvovaginitis with oral lactobacillus was 1.06 (95% confidence interval 0.58 to 1.94) and with vaginal lactobacillus 1.38 (0.75 to 2.54). Compliance with antibiotics and interventions was high. The trial was terminated after the second interim analysis because of lack of effect of the interventions. Given the data at this time, the chances of detecting a significant reduction in vulvovaginitis with oral or vaginal lactobacillus treatment were less than 0.032 and 0.0006 respectively if the trial proceeded to full enrollment.
  
  
  CONCLUSIONS
  The use of oral or vaginal forms of lactobacillus to prevent post-antibiotic vulvovaginitis is not supported by these results. Further research on this subject is unlikely to be fruitful, unless new understandings about the pathogenesis of post-antibiotic vulvovaginitis indicate a possible role for lactobacillus.
authors.affiliation: Department of General Practice, 200 Berkeley Street, Carlton, Victoria, Australia, 3053. m.pirotta@unimelb.edu.au
authors.forename: Marie
authors.initials: M
authors.lastname: Pirotta
authors.forename: Jane
authors.initials: J
authors.lastname: Gunn
authors.forename: Patty
authors.initials: P
authors.lastname: Chondros
authors.forename: Sonia
authors.initials: S
authors.lastname: Grover
authors.forename: Paula
authors.initials: P
authors.lastname: O'Malley
authors.forename: Susan
authors.initials: S
authors.lastname: Hurley
authors.forename: Suzanne
authors.initials: S
authors.lastname: Garland
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002181:Candidiasis, Vulvovaginal / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007778:Lactobacillus; D008875:Middle Aged; D016896:Treatment Outcome; D014848:Vulvovaginitis / Q000517:prevention & control
chemical_list: D000900:Anti-Bacterial Agents